Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Dollar Holds Steady Ahead of U.S. CPI as Oil Surge, Middle East Tensions Keep Markets on Edge 
Oil Prices Jump as U.S.-Iran Conflict and Strait of Hormuz Tensions Shake Global Markets 
Trump Administration Bars U.S. Travelers From Congo Flights Amid Ebola Outbreak 
Oil Prices Surge as U.S.-Iran Conflict Escalates and Strait of Hormuz Risks Grow 
Australia Consumer Sentiment Rises in July as Fuel Price Relief Lifts Confidence 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Asian Stocks Slide as Oil Surge, U.S.-Iran Tensions and Fed Rate Bets Weigh on Markets 
South Korea’s KOSPI Triggers Trading Curb as AI Chip Stock Selloff Deepens 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
Drugmakers including Pfizer Inc, GlaxoSmithKline PLC , Bristol Myers Squibb, AstraZeneca PLC and Sanofi SA will raise prices in the US on over 350 unique drugs in early January.
The increases are in preparation for the Inflation Reduction Act (IRA), which allows the government's Medicare health program to negotiate prices for some drugs starting in 2026.
The pharmaceutical industry is also dealing with inflation and supply chain constraints that increased manufacturing costs.
The price hikes are based on list prices, which do not account for other discounts or rebates to pharmacy benefit managers.
According to data released by 46brooklyn, a drug pricing non-profit affiliated with 3 Axis, drugmakers increased prices on more than 1,400 pharmaceuticals in 2022. Since 2015, there have been the most rises.
According to Antonio Ciaccia, president of 3 Axis, drugmakers have concentrated on releasing their medications at higher prices due to the concentration on annual price hikes.
More drug prices are likely to be announced over the course of January - historically the biggest month for drugmakers to raise prices.
Pfizer has so far disclosed the biggest price hikes, with 89 different prescription names seeing a rise in price in addition to an extra 10 drug brands at its Hospira division.
Then came GSK, which has already announced hikes for 26 different medications, including nearly a 7% rise for its well-known shingles vaccine Shingrix.
